Navigation Links
BioRestorative Therapies, Inc. Announces Upgrade to OTCQB Market
Date:8/22/2011

JUPITER, Fla., Aug. 22, 2011 /PRNewswire/ -- BioRestorative Therapies, Inc. (OTCQB: SCLZ) (the "Company") today announced that, based upon the Company's filing of its Quarterly Report on Form 10-Q with the Securities and Exchange Commission, the Company's common stock is now being traded on the OTCQB market, the middle tier of the OTC Market, which has been established for companies that are subject to the reporting requirements of the SEC, instead of on the OTC Pink market, the lowest tier of the OTC Market.

Mark Weinreb, the Company's Chairman and Chief Executive Officer, said, "We are very excited that the Company has made such significant strides in its development and maturation and is now a fully reporting company on a market that was established for companies that have made the substantial commitment to investor disclosure by registering and reporting with the SEC."

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.'s goal is to become a medical center of excellence using cell and tissue protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. In June 2011, the Company launched a platform technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the ThermoStem Program.  The ThermoStem Program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders.  As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for clinical procedures and outcomes for future personal medical applications.  The Company also plans to offer and sell facial creams and products under the Stem Pearls™ brand.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:
Mark Weinreb
CEO
Tel: (561) 904-6070
Fax: (561) 429-5684


'/>"/>
SOURCE BioRestorative Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
2. Course correction needed for Alzheimers therapies, experts warn
3. ShangPharma Announces Second Quarter 2011 Results
4. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
5. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
6. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
7. Neurologix Announces Second Quarter 2011 Financial Results
8. Bion Announces New U.S. Patent for Phosphorus Removal
9. ViaCyte Announces Executive Management Changes
10. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
11. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... OF PRUSSIA, PA (PRWEB) , ... January 18, ... ... disrupt clinical operations again at the CHI SCOPE Summit for Clinical Ops Executives ... AstraZeneca in engaging panel discussions to examine vital clinical research issues such as ...
(Date:1/18/2017)... , Jan. 18, 2017 Shareholder rights law ... into whether the board members of CoLucid Pharmaceuticals, Inc. ... in connection with the proposed sale of the Company ... company that develops small molecules for the acute treatment ... announced it had signed a definitive merger agreement with ...
(Date:1/18/2017)... India , Jan. 18, 2017  Market Research Future published ... Diagnostics Market is expected to grow at a CAGR of 12% ... ... disease caused due to the abnormal cell division without any control. ... cause harm to them. These cancer cells can spread to other ...
(Date:1/17/2017)... 2017  An international team of researchers from ... Boniface Hospital Albrechtsen Research Centre/University of Manitoba have ... health need affecting nearly one in 15 Americans. ... their results identify small molecule drugs with neuroprotective ... injury in animal models of metabolic, chemical and ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/8/2016)... India , Dec. 8, 2016 Market Research Future ... Service Market. The global Mobile Biometric Security and Service Market is ... 2016 to 2022. Market Highlights: ... , , Mobile ... pace due to the increasing need of authentication and security from ...
(Date:12/7/2016)... December 7, 2016 According to a new market research ... Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region - ... grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, ... Continue Reading ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):